Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Satellos Bioscience Inc. (MSCLF)

Other OTC - Other OTC Delayed Price. Currency in USD
0.21750.0000 (0.00%)
At close: 02:24PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2175
Open0.1934
BidN/A x N/A
AskN/A x N/A
Day's Range0.2175 - 0.2175
52 Week Range0.0220 - 1.0000
Volume11,000
Avg. Volume2,961
Market Cap9.091M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Satellos Bioscience Announces Development Candidate

    - SAT-3153 Designated for pre-IND Studies - Toronto, Ontario--(Newsfile Corp. - January 3, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, is pleased to announce that it has designated SAT-3153 for development towards an IND filing."We are thrilled to be in a position to move SAT-3153 ..

  • Newsfile

    Satellos Bioscience Announces Q3 2022 Financial Results and Operational Highlights

    Toronto, Ontario--(Newsfile Corp. - November 23, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a drug discovery company developing therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, announced today its financial results and operational highlights for the quarter ending September 30, 2022. The Company's interim condensed consolidated financial statements for the quarter ended September 30, 2022, a

  • Zacks Small Cap Research

    MSCLF: Initiating Coverage of Satellos Biosciences; A Muscle Regeneration Company…

    By David Bautz, PhD OTC:MSCLF READ THE FULL MSCLF RESEARCH REPORT We are initiating coverage of Satellos Biosciences Inc. (OTC:MSCLF) with a $0.70 valuation. Satellos is a biopharmaceutical company developing treatments for muscle diseases, including muscular dystrophies and muscle loss associated with chronic illness and aging. Satellos’ core technology is based on discoveries by its scientific

Advertisement
Advertisement